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BACKGROUND: The Short Course Oncology Therapy (SCOT) study is an international, multicentre, non-inferiority randomised
controlled trial assessing the efficacy, toxicity, and cost-effectiveness of 3 months (3 M) versus the usually given 6 months (6 M) of
adjuvant chemotherapy in colorectal cancer.
METHODS: In total, 6088 patients with fully resected high-risk stage II or stage III colorectal cancer were randomised and followed
up for 3–8 years. The within-trial cost-effectiveness analysis from a UK health-care perspective is presented using the resource use
data, quality of life (EQ-5D-3L), time on treatment (ToT), disease-free survival after treatment (DFS) and overall survival (OS) data.
Quality-adjusted partitioned survival analysis and Kaplan–Meier Sample Average Estimator estimated QALYs and costs. Probabilistic
sensitivity and subgroup analysis was undertaken.
RESULTS: The 3 M arm is less costly (-£4881; 95% CI: -£6269; -£3492) and entails (non-significant) QALY gains (0.08; 95% CI: −0.086;
0.230) due to a better significant quality of life. The net monetary benefit was significantly higher in 3 M under a wide range of
monetary values of a QALY. The subgroup analysis found similar results for patients in the CAPOX regimen. However, for the
FOLFOX regimen, 3 M had lower QALYs than 6 M (not statistically significant).
CONCLUSIONS: Overall, 3 M dominates 6 M with no significant detrimental impact on QALYs. The results provide the economic
case that a 3 M treatment strategy should be considered a new standard of care.
British Journal of Cancer (2018) 119:1332–1338; https://doi.org/10.1038/s41416-018-0319-z
INTRODUCTION
Colorectal cancer (CRC) affects 1.36 million patients worldwide
each year, and in the UK, is the fourth most common malignancy,
accounting for 12% of all new cancer cases each year—~41,265 in
2014.1 The cost of treatment for CRC within the first year of
diagnosis is considerably larger than that for treating other
common cancers such as breast, lung and prostate, and it is
estimated that CRC costed the English health-care system £542
million in 2010.2 Many authors have also commented on the rising
cost of cancer care3 and the challenge this presents for high
income countries to provide care to increasing populations of
cancer patients.
Given recent budget restrictions and rising pressure on health-
care systems around the world, there is a need to ensure that
cancer treatments offer the best value for money and provide
policy makers with up-to-date information on both effectiveness
and cost-effectiveness to help inform efficient allocation of health-
care resources. In the treatment of CRC, adjuvant chemotherapy is
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more effective than surgery alone for patients with fully resected
CRC at stage III4–11 and, to a lesser extent, at high-risk stage II.12–14
However, the current 6 month standard duration of adjuvant
chemotherapy is associated with considerable side effects15,16,
which impact on patient quality of life. It has previously been
unknown whether 3 months of adjuvant chemotherapy treatment
duration could reduce these side effects with no detrimental
impact on efficacy. Given the escalating cost of chemotherapy
treatments of CRC17, it is pertinent that the cost-effectiveness of
alternative treatment durations and regimens18,19 is explored.
This paper reports on an economic evaluation undertaken
alongside the Short Course Oncology Trial (SCOT) randomised
controlled trial (ISRCTN No: 23516549) to explore the cost-
effectiveness of 3 month (3 M) versus 6 months (6 M) adjuvant
chemotherapy treatment in stage III/high-risk stage II CRC
patients.
METHODS
The SCOT trial (ISRCTN No.: 23516549) was an international phase
III randomised controlled trial, to assess non-inferiority of 3 M
versus 6 M of oxaliplatin/FP adjuvant chemotherapy in stage III/
high-risk stage II CRC patients. Patients were randomised to
receive either 3 or 6 months of oxaliplatin-containing adjuvant
treatment. The chemotherapy regimen (FOLFOX or CAPOX) was at
the choice of the patient and/or physician prior to randomisation.
The trial recruited 6088 patients across six countries (UK, Denmark,
Spain, Sweden, Australia and New Zealand), followed up for a
minimum of 3 years, up to 8 years post randomisation. SCOT was
designed as a non-inferiority trial, aiming to exclude a maximum
2.5% fall in in 3-year disease-free survival from halving the
adjuvant treatment duration. Secondary endpoints were overall
survival, toxicity, quality of life and cost-effectiveness. Further
details of the intervention, randomisation, methods and outcomes
for the SCOT trial are reported elsewhere.20
The aim of the economic evaluation is to explore the treatment
and hospitalisations costs, quality of life and survival outcomes of
3 M versus 6 M adjuvant chemotherapy treatment within the
timeframe of the SCOT clinical trial.
The cost-effectiveness analysis was undertaken from the
perspective of the UK NHS and Personal Social Services for the
2016 base year, adhering to good practice guidelines.21,22 A
within-trial analysis utilised the individual patient-level data on
resource use, quality of life (EQ-5D-3L) and survival. The cost (C)
and quality-adjusted life year (QALY) outcomes for each arm are
estimated and combined with the UK decision threshold for cost-
effectiveness (λ) of £30,000/QALY21 to report outcomes in terms of
Net Monetary Benefit (NMB), according to good reporting practice
guidance.23 (NMB is calculated by monetarising the measure of
effectiveness (QALYs) by explicitly incorporating the decision
threshold (λ), and then subtracting the cost (C) to determine
whether the NMB is greater than zero. Specifically: NMB=QALY ×
λ –C. The strategy with the greatest NMB is the cost-effective
choice.) The incremental NMB is the difference between the NMB
of the two arms.
Outcomes
The effectiveness measure for the economic analysis is the
discounted QALY gains per patient in each of the study arms.
QALYs are calculated using quality-adjusted survival analysis.24
Overall survival is partitioned into three different health states:
time on treatment (ToT), disease-free survival after treatment
(DFS) and recurrence. The Kaplan–Meier survival estimates are
used for the computation of the quality-adjusted survival time in
each health state over the 8 year within-trial period.
A separate model estimated quality of life for each health state.
EQ-5D-3L data collected for a subsample of 1832 patients (about
30% of the study sample), at baseline and follow-up, and
combined with the UK EQ-5D-3L health utility scores25 to calculate
utilities. A linear regression with standard errors clustered at the
individual level estimated quality of life including independent
variables: health states, treatment group and individual
characteristics.
Time in the health states ToT, DFS and recurrence was
computed by integration of the Kaplan–Meier curves and then
adjusted by quality of life using the method of integrated quality-
survival product24 to compute QALYs. This approach to quality-
adjusted survival analysis avoids problems of informative censor-
ing in survival analysis based on individual QALYs as an
endpoint.26
Costs
Costs were calculated by the measurement and valuation of
resources used by the SCOT trial participants during the treatment
and follow-up periods. The trial collected patient-level resource
use data on adjuvant chemotherapy doses and duration and
hospitalisations during treatment and follow-up for the whole
study sample. All costs have been valued in 2016 pounds sterling.
Adjuvant chemotherapy: The doses of Oxaliplatin, Capecitabine,
5-fluouracil bolus injection and 5-fluorouracil continuous infusion
were collected and combined with their respective unit costs. The
cost per mg of each drug is obtained from the British National
Formulary 7327 as detailed in Table S1 in the supplementary
material.
Hospitalisation: Hospitalisation costs are incurred by patients for
receiving adjuvant chemotherapy during the treatment period
and also for treating adverse reactions. Hospitalisation resource
use data include night stays in intensive care unit (ICU), high
dependency unit (HDU), general medicine, and in-patient
chemotherapy (IP) as well as day cases (DC) and outpatient
attendances (OP). The direct and non-direct costs for each
hospitalisation were obtained from the Information Services
Division (ISD)28 of the National Health Service Scotland. Direct
costs can be classified by medical, nursing, health professionals,
pharmacy, theatre, laboratory and others. For IPs and DCs
occurring within the treatment period, the pharmacy cost is
subtracted to avoid double counting of chemotherapy medica-
tion. Table S2 in the supplementary material details unit costs for
each type of hospitalisation. These costs include staff administra-
tion time, e.g., for delivering the adjuvant chemotherapy, in
medical and nursing costs and non-direct costs when a
hospitalisation or appointment for chemotherapy has occurred.
The cost of treating adverse events is assumed to be included in
hospitalisation costs for patients attending hospital for night, day
case or outpatient visit after having adverse reaction.
Kaplan–Meier Sample Average (KMSA) Estimator: Given that the
follow-up period differed among patients total cost per patient is
estimated by the KMSA estimator.29 This way the average total
cost is estimated as the sum of the average cost for each period
multiplied by the probability of surviving at the beginning of the
period.
Cost-effectiveness outcome
The analyses were performed using STATA 14.0 (StataCorp, TX,
USA) to compare the mean costs, and mean QALY differences
between the comparator groups (3 months vs. 6 months
treatment) and the NMB is reported in line with recent reporting
guidelines23 and the UK reference case.21 Discounting of costs and
QALY outcomes beyond 1 year was applied at 3.5% rate as
recommended.21
Missing data
Only a subgroup of patients reported EQ-5D health status
following recommendations to discontinue data collection based
on an interim study analysis.30 To control for plausible differences
between the EQ-5D sample and the total study sample the quality
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of life model includes co-variables such as planned treatment,
high-risk disease (T4 or N2 as previously defined20), gender, age
and ethnicity. The model predicts health utilities for the average
characteristics of the patients in each health state.
Sensitivity analysis
Bootstrapping (1000 iterations)31 was used to account for
uncertainty around the difference in costs and QALYs and how
this uncertainty impacts on the cost-effectiveness outcome. The
uncertainty is reported through confidence intervals and the
computation of cost-effectiveness acceptability probabilities
estimated as a function of the threshold for the monetary value
of a QALY.32
Subgroup analyses was undertaken, in line with the main trial
analysis,20 to consider cost-effectiveness of the two treatment
duration strategies according to: planned treatment regimen,
CAPOX/FOLFOX; disease risk, high/low risk stage III; gender; and
age.
RESULTS
Health outcomes
In total, 6088 patients were randomised in the SCOT study,
however, only 6065 patients are considered in the analysis since
23 patients withdrew consent to use their data at follow-up.20
Table 1 illustrates how overall expected survival time, over 8 years
after randomisation, is split into ToT, DFS and recurrence. ToT
is significantly higher in the 6 M arm while DFS just fails
to significantly favour the 3 M arm at 5% of error. No statistically
significant differences are found for time in recurrence or overall
survival. Figure 1 shows the area representing ToT, DFS and
recurrence time generated from Kaplan–Meier estimates (see
more detailed Kaplan–Meier curves in supplementary material:
Figures S1, S2 and S3).
Quality of life
Table 2 shows the results of the utility model for non-missing
observations. The effect of recurrence and time on treatment is
capture by two indicators taking value 1 for all those EQ-5D
responses occurring in those health states. ToT and recurrence
have a significant negative effect on utility, as could be expected.
The 3 M arm is estimated to have higher quality of life (P-value <
0.05) even after controlling for recurrence and time on treatment.
These results are consistent with the higher incidence of adverse
events in the 6 M groups compared with the 3 M arm. For
example, the main long-term adverse event was neuropathy
associated with the Oxaliplatin component of the chemotherapy
regimen. Specifically, 58% of patients in the 6 M arm had
peripheral neuropathy equal or worse than Grade 2, the same
figure for the 3 M arm was 25%. Patients’ characteristics are
included in the model to adjust health utilities to the average
values of the whole SCOT sample, with and without EQ-5D data
(see Table S3 in supplementary material for differences in
characteristics between subsamples). Significant characteristics
are male and age, with a positive effect, and ethnicity, with a lower
quality of life for African/Caribbean patients and South Asian with
respect to White/Caucasian. No significant variables are planned
treatment and disease risk. The results of the model follow the
pattern of the evolution of EQ-5D scores over time for both arms
in Fig. 2. Figures S1–S5 From randomisation point quality of life
decreases for both arms up to 3 months. At this point health
utilities for those in 3 M arm increases as they finish treatment
while those patients in the 6 M arm continue with lower quality of
life. Changes in quality of life are related to time on treatment
although differences between the two arms remain after receiving
adjuvant chemotherapy to some extent.
Costs
Table 3 details cost incurred by patients in both arms, with a
breakdown of the hospitalisation costs over different time periods.
As expected, adjuvant chemotherapy costs are higher in the 6 M
arm. Hospitalisation costs differ between arms in the 4–6-month
period, as could be expected; however, the data also reveal that
patients in the 6 M arm experience more hospitalisation costs in
the 7–12-month period, possibly reflecting longer lasting compli-
cations due to the longer treatment period. Interestingly, the costs
during the first 6 months after randomisation are not doubled for
the 6 M arm. Specifically, adjuvant chemotherapy and hospitalisa-
tion costs are only 1.67 and 1.45 times higher, respectively, in the
6 M arm. This is due to tolerability of treatment where many
patients randomised to 6 M do not complete the full course of
treatment. While 83.3% of patients randomised to 3 M received
the full 3 months treatment, only 58.8% of those randomised to
6 M received 6 months treatment.20 Notice that the health
economic evaluation is clearly justified in the context of this
study to analyse the actual consequences on costs from reducing
the intended treatment duration from 6 to 3 months. There is no
difference in cost between arms beyond 12 months. Overall, the
cost is significantly greater in the 6 M arm, driven by hospitalisa-
tions (-£2835) in the first 6 months to a higher extent than by
received adjuvant chemotherapy (-£1829). A detailed analysis of
resource use, regarding adjuvant chemotherapy and hospitalisa-
tions, can be found in Tables S4 and S5, respectively, in
the supplementary material.
Cost-effectiveness analysis
Table 4 details the results of the base case cost-effectiveness
analysis. The 3-month adjuvant chemotherapy strategy is sig-
nificantly cheaper, costing £4,881 less than the 6 M strategy over
the 8 year analysis period. The 3 M strategy also results in the
greatest QALY gain expected, although this is not statistically
significant (P-value= 0.33) and results in uncertainty in the QALY
gains as seen in the 95% confidence intervals. The QALY gains for
the 3 M arm are driven by the significant improvement in
quality of life rather than life expectancy (LE), indeed the
6 M arm has a very small non-significant improvement in LE
(P-value= 0.69), meeting the non-inferiority margin for survival
specified for the SCOT trial.20 These cost-effectiveness results
indicate that the 3 M treatment strategy is dominant (cost saving
with improvement in QALYs), with an incremental NMB of £7246
per patient. 3 M strategy is therefore the cost-effective option,
with 99% probability of being cost-effective at the UK decision
threshold of £30,000/QALY.21 The 3 M also remains the optimal
choice across a wide range of willingness to pay values (see
Figure S4 in supplementary material for the cost-effectiveness
acceptability curve).
Table 1. Overall survival time by health state (ToT, DFS and
recurrence) and by arm
3M 6M Incremental
Survival analysis Mean Mean Mean P-value
N 3035 3030 6065
ToT 0.21 0.39 −0.18 0.000
DFS 5.93 5.74 0.19 0.053
Recurrence 0.73 0.77 −0.041 0.605
Total (OS) 6.87 6.90 −0.032 0.695
Kaplan–Meier estimates used for computation of expected time in each
health state
Survival time estimated up to 8 years post randomisation
Estimation sample in the case of ToT is lower due to missing values, 3018
and 3013 patients for the 3 M and 6M arms, respectively
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Subgroup analysis
Table S6 illustrates the cost-effectiveness for the subgroup
analyses according to: (i) treatment regimen, (ii) risk, (iii) gender
and (iv) age. For all the subgroups except FOLFOX treatment and
males, the cost-effectiveness results are similar to the base case
analysis with the 3 M arm dominating and a 99% probability of
being the cost-effective option. In the FOLFOX treatment group,
the 3 M arm shows cost saving, but also fewer QALY gains, which
were not significant but driven by a small gain in LE for the 6 M
arm. The relative advantage of the 3 M arm in QALYs is higher for
the CAPOX treatment, high-risk patients, females and older
patients. An interaction test of differences in incremental QALYs
between subgroups conclude that only the treatment regimen
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Fig. 1 Overall survival partitioned into time on treatment (ToT), disease free survival after treatment (DFS), and recurrence. Kaplan-Meier
estimates over 8 years and by arms
Table 2. Health utilities regression
Variable Coef. S.E.
N-observations 16,091
N-patients 1757
Health states (ref: disease free)
On treatment −0.0394*** 0.00408
Recurrence −0.0578*** 0.0139
Arm: 6 months −0.0154* 0.00730
Characteristics
CAPOX 0.00402 0.00783
High risk −0.00911 0.00724
Male 0.0159* 0.00733
Age 0.00162*** 0.000429
Ethnic (ref: White/Caucasian)
African/Caribbean −0.0810* 0.0385
South Asian −0.145** 0.0536
Chinese −0.0447 0.0772
Other 0.0178 0.0217
Constant 0.866*** 0.00944
Standard errors (S.E.) clustered at the patient level
P-values: *P < 0.05, **P < 0.01, ***P < 0.001
N-observations refer to the number of EQ-5D questionnaires reported in
total by the N-patients included in the estimation
The constant in the model refers to a 65-year-old female patient, in
disease-free health state in the 3 months arm, receiving FOLFOX treatment,
with low risk stage III and White/Caucasian ethnicity
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Fig. 2 Evolution of EQ-5D utilities over time by arms. Average and
95% CI
Table 3. Costs by treatment duration (£/patient)
Time from beginning of
treatment
3 M 6M Incremental
Mean Mean Mean P-value
N 3035 3030 6065
Adjuvant chemotherapy 2750 4579 −1829 < 0.001
Hospitalisation (0–3 months) 3576 3595 −19 0.816
Hospitalisation (4–6 months) 1790 4185 −2395 < 0.001
Hospitalisation (7–12 months) 2748 3054 −306 0.030
Hospitalisation ( > 12 months) 8473 8588 −115 0.876
Total hospitalisation 16587 19422 −2835 < 0.001
Total 19337 24001 −4663 < 0.001
Figures refer to non-discounted average cost for each period conditional
on survival
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subgroup shows a statistically significant difference in QALY
differences, CAPOX (0.19 Incremental QALYs) and FOLFOX (−0.12
Incremental QALYs) with a P-value= 0.066. This relative advantage
of the 6 M for the FOLFOX subgroup is driven by life expectancy
(see Table S7 in supplementary material for a detailed subgroup
survival analysis). While for the CAPOX regimen, life expectancy is
better for the 3 M arm by 0.07 years, patients treated with FOLFOX
have a greater life expectancy in the 6 M arm, by 0.22 years
(interaction test, P-value= 0.106). In the FOLFOX subgroup, the 3
M arm still maintains a greater NMB than 6 M, with an incremental
NMB of £3229 and a 77% probability of being cost-effective given
a UK threshold of £30,000/QALY. Therefore, the 6 M arm would not
be considered cost-effective and the 3 M treatment duration
remains the optimal treatment strategy.
The interaction test of differences in incremental QALYs
between the risk, gender and age subgroups showed no
significant differences in incremental QALYs.
For each subgroup, the 3M strategy has the highest probability of
being cost effective for a wide range of monetary values of a QALY
(see Figure S5 in supplementary material for the cost-effectiveness
acceptability curves). Only when a threshold higher than £60,000/
QALY is considered the 6M arm becomes the cost-effective strategy
(with highest probability) for the FOLFOX subgroup.
DISCUSSION
The results of the economic evaluation show that the 3-month
duration arm is clearly a cheaper intervention and the dominant
strategy for chemotherapy treatment for high-risk stage II and
stage III CRC. A short treatment duration significantly reduces
costs by saving resources related to adjuvant chemotherapy and
hospitalisations. The 3 M arm also significantly improves patient
quality of life during the treatment period, with no significant
impact on overall survival, leading to an overall QALY gain for the
3 M arm, albeit not statistically significant. The probabilistic
analysis and exploration of cost-effectiveness acceptability
showed little uncertainty in the economic results over a wide
range of willingness to pay thresholds.
An exploration of four subgroup analyses indicates similar
conclusions, with the 3 M arm being the dominant or cost-
effective strategy given the UK £30,000 per QALY threshold. The
type of chemotherapy received has the greatest subgroup impact
on cost-effectiveness. The interaction between planned treatment
and QALY differences between the two arms is statistically
significant. In the analyses of the FOLFOX chemotherapy regimen,
the 6 M arm generated more QALYs than the 3 M arm, primarily
driven by the higher estimated disease free and overall survival,
which was explored and discussed in the main study analyses.20
The quality of life difference between arms is in favour of the
3 month arm, yet the survival gains in the FOLFOX regimen are
relevant over the 8 year follow-up period, resulting in an overall
QALY gain. Nonetheless, at a decision threshold of £30,000/QALY
the NMB is larger for the 3 M arm (incremental gain of £3229 per
patient) and therefore the 6 M duration would not be considered
cost-effective from a UK perspective.21
Strengths: The 8 year patient follow-up allowed exploration of
the cost-effectiveness outcomes over this long time period. The
key cost differences occur within the first year after randomisation,
where the 6 M arm costs nearly double the 3 M arm in
chemotherapy and hospitalisations. Between years 1 to 8 there
is little difference in hospitalisations between arms, yet over the 8-
year analysis period the total costs per patient are significantly
different between arms, favouring the 3 M arm. We would not
expect longer-term differences in costs between arms. The follow-
up also allows a thorough consideration of the QALY results which
are driven by the timing of events. There are small differences in
life expectancy which are subject to uncertainty in both the base
case and subgroup analyses, yet, overall quality of life is
consistently higher in the 3 M arm in all analyses. The maximum
advantage in quality of life is between 3 to 6 months post
randomisation where the 3 M arm have stopped treatment. The
detrimental quality of life impact on the 6 M arm remains due to
the adverse event derived from chemotherapy.30
Limitations: Data present censoring given the minimum of 3-
year follow up and the relatively high survival rates after 8 years
(about 75%). This aspect could be affecting the results to some
extent. The cost and quality-adjusted survival methodology used,
i.e., KMSA and partitioned survival analysis respectively, is chosen
to reduce censoring-related biases.
This study was undertaken using the within-trial 8 years time
horizon. The analysis shows that the key differences between arms
in terms of costs and quality of life occur mainly within the first
year, and beyond this point there are no significant differences
between the two strategies. Nonetheless, extrapolation beyond
the 8 years is unlikely to change the outcomes and conclusions
unless we anticipate huge differences in survival.
CONCLUSION
This study found that compared with the traditional 6-month
chemotherapy treatment period, a 3 months treatment strategy
costs significantly less with no significant detrimental impact on
patient outcomes (quality of life and survival) and therefore is
found to dominate. Three months chemotherapy treatment for
patients with stage III and high-risk stage II CRC is the optimal
treatment strategy from an UK health-care perspective. Cost-
effectiveness is affected by the type of chemotherapy regimen
used, however, the 3 M strategy remains the optimal choice for
both the CAPOX and FOLFOX regimens under a policy relevant
willingness to pay thresholds.
The SCOT trial was the largest randomised study in adjuvant
treatment of CRC to date, which showed that 3M treatment is non-
inferior to 6M treatment in the overall trial population. This economic
evaluation undertaken alongside SCOT adds to the evidence showing
Table 4. Estimates of costs and QALYs for the two strategies
Intervention strategies Costs (£/patient) LE QALYs NMB (£30 K/QALY) Prob CE λ= £30,000
Mean [95% CI] Mean [95% CI] Mean [95% CI] Mean [95% CI]
3 Months 18,401 [17,538; 19,328] 6.87 [6.73; 6.99] 5.30 [5.17; 5.40] 140492 [135,327; 145,658] 0.995
6 Months 23282 [22,227; 24,367] 6.90 [6.78; 7.02] 5.22 [5.10; 5.34] 133246 [129,569; 136,922] 0.005
Incremental −4881 [−6269; −3492] −0.03 [−0.22; 0.13] .08 [−0.086; 0.230] 7246 [3469; 11,023] (3 M dominates)
Health utilities conditional on survival considered
KMSA estimator and partitioned survival analysis used for costs and QALYs, respectively
CIs are computed using bootstrap sampling
Probability of cost-effectiveness calculated using 1000 bootstrap replications
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that the 3M treatment strategy is not only cost-effective, but a
dominant treatment strategy with little uncertainty in the cost-
effectiveness decision; thus providing the economic case that a 3M
treatment strategy should be considered a new standard of care.
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